Articles

admin

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FOSTER CITY, Calif.–(BUSINESS WIRE)– Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on January 10, 2023, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 23,900 shares of common stock and 12,000 restricted stock units (“RSUs”) to four new employees under Mirum’s 2020 Inducement Plan. The Compensation…

View details
Glycomine Announces First Patient Dosed in Phase 2 Clinical Study of GLM101, a Potential Treatment for PMM2-CDG

SAN CARLOS, Calif., January 9, 2023 – Glycomine, Inc., a clinical-stage biotechnology company focused on developing new therapies for orphan diseases, today announced that the first patient has been dosed in a multi-center open-label Phase 2 study (ClinicalTrials.gov Identifier: NCT05549219) of GLM101, a targeted mannose-1-phosphate replacement therapy, in adult patients with phosphomannomutase 2-congenital disorder of glycosylation…

View details
4D Molecular Therapeutics Announces Updates on Clinical Pipeline and Additional Preclinical Programs

January 9, 2023 Download PDF EMERYVILLE, Calif., Jan. 09, 2023 (GLOBE NEWSWIRE) — 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted genetic medicines, announced product pipeline portfolio updates and preclinical product candidate additions for its large market ophthalmology and pulmonology programs, as well as clinical…

View details
Mirum Pharmaceuticals Announces Preliminary Unaudited LIVMARLI 2022 Net Revenue and Provides Corporate Updates

– $76 million in total revenue and $74 million net product sales anticipated for LIVMARLI for 2022, preliminary and unaudited – sNDA for LIVMARLI in PFIC submission planned for first quarter 2023 – Multiple data analyses planned in 2023 advancing late-stage cholestasis programs FOSTER CITY, Calif.–(BUSINESS WIRE)– Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today provided a preview…

View details
Mirum Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023

FOSTER CITY, Calif.–(BUSINESS WIRE)– Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the identification, acquisition, development and commercialization of novel therapies for debilitating rare and orphan diseases, today announced that it will present at the annual J.P. Morgan Healthcare Conference taking place January 9-12, 2023. Presentation and Q&A Session Visit the Investors and Media section of…

View details
System analytics
Leave a comment

What we do Maecenas et felis consequat Nullam mollis – massa id volutpat. Suspendisse neque elit, consequat nec tempus sit amet, luctus id erat volutpat magna. Integer nec viverra mauris Suspendisse ipsum – amet neque elit, consequat nec tempus sit amet, luctus id erat volutpat magna. Integer nec viverra mauris. Integer eu aliquet dolor. Suspendisse…

View details
Human resources
Leave a comment

What we do Maecenas et felis consequat Nullam mollis – massa id volutpat. Suspendisse neque elit, consequat nec tempus sit amet, luctus id erat volutpat magna. Integer nec viverra mauris Suspendisse ipsum – amet neque elit, consequat nec tempus sit amet, luctus id erat volutpat magna. Integer nec viverra mauris. Integer eu aliquet dolor. Suspendisse…

View details
Brand & strategy
Leave a comment

What we do Maecenas et felis consequat Nullam mollis – massa id volutpat. Suspendisse neque elit, consequat nec tempus sit amet, luctus id erat volutpat magna. Integer nec viverra mauris Suspendisse ipsum – amet neque elit, consequat nec tempus sit amet, luctus id erat volutpat magna. Integer nec viverra mauris. Integer eu aliquet dolor. Suspendisse…

View details
Marketing planning
Leave a comment

What we do Maecenas et felis consequat Nullam mollis – massa id volutpat. Suspendisse neque elit, consequat nec tempus sit amet, luctus id erat volutpat magna. Integer nec viverra mauris Suspendisse ipsum – amet neque elit, consequat nec tempus sit amet, luctus id erat volutpat magna. Integer nec viverra mauris. Integer eu aliquet dolor. Suspendisse…

View details
Business optimisation
Leave a comment

What we do Maecenas et felis consequat Nullam mollis – massa id volutpat. Suspendisse neque elit, consequat nec tempus sit amet, luctus id erat volutpat magna. Integer nec viverra mauris Suspendisse ipsum – amet neque elit, consequat nec tempus sit amet, luctus id erat volutpat magna. Integer nec viverra mauris. Integer eu aliquet dolor. Suspendisse…

View details